Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

South Korea Anxiety Disorder and Depression Market Outlook

The South Korea anxiety disorder and depression market is expected to grow at a CAGR of 3.8% between 2024 and 2032. UNICEF and BTS’ collaboration for LOVE MYSELF CAMPAIGN, along with COVID-19 and lockdown significantly propel the growth if the industry in South Korea.

south korea anxiety disorder and depression market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the South Korea Anxiety Disorder and Depression Market

Genetic, biochemical, psychological, and environmental elements may all play a role in the development of depression. A gloomy day or a sad mood are not the only symptoms of depression. A person may be depressed if a depressive state persists for a long time and interferes with daily activities. Anxiety disorders go beyond momentary uneasiness, stress, or worry. For those who suffer from an anxiety disorder, the symptoms may even worsen with time if coping strategies and professional help aren't taken. The symptoms usually hamper daily tasks, including work and academic-related performance and interpersonal connections, among others. Generalized anxiety disorder, social anxiety disorder, and several phobia-related illnesses are only a few of the forms of anxiety disorders.

Increasing Awareness and Growing Acceptance of Mental Health Issues Among People

As per the World Health Organization (WHO), South Korea has the fourth-highest suicide rate  in the world. Suicides among the elderly are one cause of their high suicide rate. Traditionally, children care for their aged parents. However, because this system has mostly vanished now, many older people commit suicide rather than feel like a financial burden on their relatives or family. In addition to the elderly, students also experience higher-than-average suicide rates, which may be at least partially attributed to their intense academic pressure. When students can't succeed scholastically, they could feel as if they have betrayed their families. Students may experience a higher risk of suicide due to alcohol usage, lack of sleep, and stress, which lead to mental health issues such as anxiety disorders and depression, among others.

Contribution of Celebrities such as BTS in Raising Mental Health Awareness

The LOVE MYSELF campaign , which was launched by UNICEF, the record label BigHit MUSIC, and 21st-century pop sensations BTS, was a remarkable success, spreading empowering messages of self-love and self-care to nearly every nation around the world. The LOVE MYSELF initiative has raised $3.6 million to encourage self-love and put a stop to child maltreatment and violence. Along with providing financial aid, the BTS has increased awareness through social media, generating more than 50 million interactions with postings for the LOVE MYSELF campaign since it first debuted five years ago. BTS donated revenues from LOVE MYSELF merchandise, a share of Love Yourself album sales, and an extra $1 million to UNICEF in 2021, continuing their support for the initiative. BTS played a pivotal role in spreading mental health awareness not just in South Korea but all over the world and has contributed to the expansion of the anxiety disorder and depression industry.

Opportunities and Challenges in the South Korea Anxiety Disorder and Depression Market

COVID-19 Pandemic and Lockdown for Prolong Time Period Further Boosted the Market Growth

Depression and anxiety issues are some of the most prominent mental health concerns all over the world. Due to the COVID-19 pandemic and the prolonged lockdown period, people’s physical and mental health were greatly impacted. The COVID-19 pandemic has had severe and widespread effects on health systems, the economy, and civilizations. It is one of the most significant worldwide disasters in recent generations. Many people have lost their lives or their jobs, and the normal functioning of families and communities has been disrupted. The socialisation and educational opportunities for children and teenagers have been compromised. This led to the fuel feelings of loneliness, anxiety, stress, and behavioural issues among children and youth. Adults faced a similar level of stress, especially women, which led to anxiety disorder and depression among others.

Access to Professional Help and Surge of Digital Therapeutics in the Country

With growing awareness, the acceptance of mental disorders has increased more than in earlier times. People now take the required professional help when needed. Accessibility to mental health services has immensely improved, as people can now seek help via both online and offline channels. As mental health is still considered taboo in the country, especially among the elderly, online channels such as video calls, phone calls, and chats have grown steadily in the country. Hence, many people prefer to contact psychiatrists, psychologists, or clinical psychologists via online mode. 

Minds AI is developing a mental health counselling and treatment programme for the people of South Korea. The company is established in a university laboratory and is working on developing an analysis programme called Minds NAVI and a virtual reality (VR) based assessment, education, and training program. This amalgamation of high technology such as AI with diagnosis processes has helped to improve the accuracy of the diagnosis and treatment. The surge of digital therapeutics has helped in increasing the reach of intervention programmes and aid the development of the anxiety disorder and depression market in South Korea.

An Increase in the Ageing Population and the Hectic Lifestyle of the Working Population are Inducing Mental Health Concerns Among the Korean Population

According to Statistics Korea, the number of aging populations  aged 65 and above in South Korea exceeded 8.5 million in 2021. Moreover, there has been a steady growth in the divorce rate among this age group and the reluctance to getting married is also bolstering among young generation. Hectic lifestyle, long working hours, and work pressure further affect the mental health of people Compared to the general population, elderly South Koreans who live alone report greater rates of psychological suffering. According to estimates, 10-20% of senior Koreans have depressive disorders, making geriatric mental health in South Korea a very significant and newly rising public health issue.

Continuous Research in the Fields of Psychology and Psychiatry, along with the Government’s Rehabilitation Programs, is Augmenting the Market Growth 

Treatment of disorders at healthcare facilities, community-based psychosocial rehabilitation, and housing, employment, and financial support are all included in mental health promotion programmes in Korea. In particular, medical diagnosis, treatment, and rehabilitation provided by public and private mental medical institutions are the treatments in medical facilities included in national programs. With the growing awareness among general people and research in the field are propelling the anxiety disorder and depression market in South Korea. 

Market Analysis

south korea anxiety disorder and depression market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on Drug class the South Korea anxiety disorder and depression market is segmented into antidepressant drugs, therapy and devices, and indication. The antidepressant segment is further classified into Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, and Beta-Blockers, among others. 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the anxiety disorder and depression market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans. 

  • Pfizer Inc.  (Pfizer Korea Co., Ltd.)
  • Eli Lilly and Company
  • H. Lundbeck A/S (Lundbeck Korea Co., Ltd.)
  • Korea Otsuka Pharmaceutical Co., Ltd.
  • Janssen Korea Co., Ltd. (Johnson & Johnson Services, Inc.)
  • Others

Market Share by Drug Class

Utilising drugs, especially antidepressants, in the treatment of depressive disorders may lessen both the personal and societal toll of depression. Tricyclic antidepressants (TCAs)  were the first-line therapy of choice for depressive disorders for many years after antidepressants were initially introduced for the treatment of depression. However, during the past few years, selective serotonin reuptake inhibitors have replaced TCAs as the first-line therapy for depression (SSRIs). The most often given first antidepressants are selective serotonin reuptake inhibitors (SSRIs), followed by more recent dual-action medications. Furthermore, ongoing trials to enhance the effectiveness of drugs and their commercialization during the forecast duration are anticipated to offer potential growth opportunities for all the antidepressants in the South Korea anxiety disorder and depression market.

Market Share by Therapy and Devices

There has been an increase in demand for counselling therapy as a result of rising suicide rates. When compared to other therapies, cognitive behaviour therapy (CBT) commands a sizeable market share. Talk therapy or psychotherapy  is one sort of mental health care. It's frequently used to treat mental illnesses, either by itself or in conjunction with other drugs. Numerous mental illnesses, such as depression, bipolar disorder, anxiety, anorexia, bulimia, and other eating disorders, as well as posttraumatic stress disorder (PTSD), can be treated with psychotherapy. Depending on the patient's needs, psychodynamic therapy and interpersonal therapy are also used.

Market Share by Indication

Obsessive-compulsive disorder (OCD)  sufferers are more likely to have various types of mental diseases. The most typical of them is major depressive disorder (MDD). Reactive stress, obsessive or compulsive behaviours, and biochemical alterations in the brain that can affect mood and behaviour are just a few of the possible reasons. OCD sufferers are particularly vulnerable to depression since it might make it difficult for the patients to follow through with the OCD symptoms therapy. Changes in serotonin synthesis and activity, a neurotransmitter that transmits messages between nerve cells, are indicators of both OCD and MDD. These symptoms are more likely to be brought on by complex phobias like agoraphobia and social phobia.

People suffering from phobias frequently make a conscious effort to avoid the source of their dread and anxiety. The everyday tasks that phobias restrict might result in significant anxiety and depression. These symptoms are more likely to be brought on by complex phobias like agoraphobia and social phobia. People who have phobias frequently make a conscious effort to avoid the source of their dread and anxiety. The interrelation among all the mentioned mental disorders is expected to bolster the sales of medication and therapy services in the country, thereby augmenting the anxiety disorder and depression market in South Korea.

south korea anxiety disorder and depression market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Pfizer Inc.  (Pfizer Korea Co., Ltd.) – Pfizer develops, manufactures, and sells biopharmaceuticals in several parts of the world. Moreover, it offers several contract manufacturing services, biosimilars, medicines, injectable drugs, and active pharmaceutical ingredients (APIs). Pfizer offers its pharmaceutical products through distributors, hospitals, clinics, pharmacies, and public institutions. Belgium, India, Ireland, China, Italy, Germany, Japan, Singapore, and the US are all significant production facilities for Pfizer Inc. The firm does business across the Middle East, Australia, Asia-Pacific, Europe, North America, South America, and Africa. The company was founded in 1849 by Charles Pfizer and Charles Erhart, and the headquarters are in New York, USA.

Eli Lilly and Company - A healthcare organisation called Eli Lilly and Co. (Lilly) is involved in the research, creation, and marketing of products for use in human healthcare. The business provides medications for neurological issues, immunological diseases, cancer, endocrinology, men's health, and musculoskeletal issues.  Lilly engages in research and development initiatives to find and provide cutting-edge medications. The company also advertises its goods through partnerships with other businesses and sales reps. Additionally, the corporation sells its goods throughout North America, Europe, South Asia, the Middle East, North Asia-Pacific regions, South America, and Africa. The company was established in 1876 by a pharmaceutical chemist, Colonel Eli Lilly.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Indication
Breakup by Drug Class
  • Antidepressant Drugs
  • Therapy and Devices
Breakup by Indication
  • Major Depressive Disorder (MDD)
  • Obsessive-Compulsive Disorder (OCD)
  • Phobia
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Pfizer Inc.  (Pfizer Korea Co., Ltd.)
  • Eli Lilly and Company
  • H. Lundbeck A/S (Lundbeck Korea Co., Ltd.)
  • Korea Otsuka Pharmaceutical Co., Ltd.
  • Janssen Korea Co., Ltd. (Johnson & Johnson Services, Inc.)
  • Others

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 3.8% between 2024 and 2032.

COVID-19 and lockdown, increased ageing population, solo living, hectic lifestyle, long working hours, online as well as offline access to mental healthcare facilities, and continuous research in the field of mental healthcare diagnosis and treatment are the major industry drivers.

BTS’ LOVE MYSELF campaign, increasing awareness and acceptance of mental disorders among people are the leading trends in the South Korea anxiety disorder and depression market.

The major players in the South Korea anxiety disorder and depression industry are Pfizer Inc.  (Pfizer Korea Co., Ltd.), Eli Lilly and Company, H. Lundbeck A/S (Lundbeck Korea Co., Ltd.), Korea Otsuka Pharmaceutical Co., Ltd., and Janssen Korea Co., Ltd. (Johnson & Johnson Services, Inc.), among others.

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Pricing Plans

Purchase Full Report

Datasheet

 

USD 2199

USD 1999

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 3299

USD 2999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 4399

USD 3999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 5499

USD 4999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-120-433-0800

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124